Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Heart scan kidney risk: to pause or not to pause your blood pressure meds?

NCT ID NCT07184918

First seen Oct 01, 2025 · Last updated Jun 22, 2026 · Updated 38 times

Summary

This study looked at 44 adults who take the blood pressure drug Ramipril and were scheduled for coronary angiography (a heart imaging test using dye). Half continued taking Ramipril as usual, while the other half stopped it 48 hours before and restarted 72 hours after the procedure. Researchers measured kidney function and injury markers to see which approach might be safer. The goal is to help doctors decide whether to pause ACE inhibitors before contrast dye exposure to reduce the risk of kidney damage.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE KIDNEY INJURY are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • Faculty of Pharmacy Tanta university

    Tanta, Gharbia Governorate, 31527, Egypt

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

Ramipril (a blood pressure medicine)

What this could lead to

If the results are clear, this could help doctors decide whether to pause or continue ACE inhibitors before heart imaging to protect the kidneys.

What could go wrong

This is a small, completed study with only 44 participants, so the findings may not apply to everyone. The study does not test a new treatment, only compares two existing approaches.

Conditions

The condition(s) this trial relates to.

acute kidney injury

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.